Pursuant to a special resolution passed by shareholders on May 6, 2020, the company has consolidated its capital on a one-new-for-20-old basis. The name of the company has not been changed.
Effective at the opening on Wednesday, Dec. 30, 2020, the common shares of Hemostemix Inc. will commence trading on the TSX Venture Exchange on a consolidated basis. The company is classified as a consumer products -- biotechnology/pharmaceuticals company.
Capitalization: unlimited shares with no par value, of which
46,368,985 shares are issued and outstanding
Escrow: nil shares subject to escrow
Transfer agent: Computershare Trust Company of Canada
Trading symbol: HEM (unchanged)
Cusip No.: 423694 30 6 (new)
© 2021 Canjex Publishing Ltd. All rights reserved.